Patients with a common heart rhythm disorder who took an experimental blood-thinning drug had far fewer bleeding episodes ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

Use of smokeless tobacco, cigars, and pipes increased the risk for coronary heart disease and heart attacks, according to a ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Three common heart conditions—heart failure, atrial fibrillation, and coronary heart disease—are closely linked to cognitive decline and a higher risk of dementia, according to a new scientific ...

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...